VERU

Veru Inc.

NASDAQ Capital Market

$14.36

Open: $16.2 High: $16.7 Low: $16.04 Close: $16.2

Range: 2022-05-18 - 2022-05-19

Volume:138,340

Market: Extended-hours

Get Free API Key

Download as Excel

VERU

Veru Inc. 2916 N. MIAMI AVENUE https://www.verupharma.com

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States.

CEO: Mitchell S. Steiner
Employees: 252
Sector: Healthcare
Industry: Drug Manufacturers

Latest Stocks Posts

View All Posts >

VERU News

Latest news about the VERU

VERU Stock Alert: 6 Things to Know as Veru Appoints a New Executive
Veru (VERU) stock is on the move Wednesday following news of the biopharmaceutical company adding Joel Batten to its list of executives.
by Investor Place at 5/18/22, 12:00 AMView More →
Catch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise
VERU stock's rapid upward trajectory could continue as Veru releases its fiscal results and marks a significant clinical milestone.
by Investor Place at 5/17/22, 12:00 AMView More →
Short Squeeze Stocks: VTNR, VERU and 3 Others Experts Think Are Ready to Pop
Short squeeze stocks are once again in focus this week as the bears continue to run wild in the stock market.
by Investor Place at 5/16/22, 12:00 AMView More →
VERU Stock Pops on a Covid-19 Treatment Milestone
Veru (VERU) stock is rising higher on Wednesday following a recent ruling from the FDA concerning the company's Covid-19 treatment.
by Investor Place at 5/11/22, 12:00 AMView More →
Veru Stock Could Face Difficulties If the Culper Research Report Is True
VERU stock could face major problems with investors if some of the glaring issues raised by the Culper Research report are true.
by Investor Place at 5/9/22, 12:00 AMView More →
BRIEF-Veru Inc Files For Up To $150 Million Of Mixed Shelf Offering
* VERU INC FILES FOR UP TO $150 MILLION OF MIXED SHELF OFFERING - SEC FILING Source text for Eikon: (https://bit.ly/38722qB) Further company coverage:
by Reuters at 6/26/20, 10:13 PMView More →
BRIEF-Veru Inc Enters Into A Common Stock Purchase Agreement
* VERU INC - ON JUNE 26, ENTERED INTO A COMMON STOCK PURCHASE AGREEMENT
by Reuters at 6/26/20, 10:04 PMView More →
BRIEF-Veru Enrolls First Patient In Phase 2 Clinical Trial Of Novel Drug, Veru-111
* VERU ENROLLS FIRST PATIENT IN PHASE 2 CLINICAL TRIAL OF NOVEL DRUG, VERU-111, TO COMBAT COVID-19 Source text for Eikon: Further company coverage:
by Reuters at 6/19/20, 12:38 PMView More →
BRIEF-Veru Posts Q2 Loss Per Share Of $0.01
* VERU REPORTS STRONG FISCAL 2020 SECOND QUARTER RESULTS AS NET REVENUES INCREASE 43%, GROSS PROFIT UP 61%
by Reuters at 5/13/20, 11:51 AMView More →
BRIEF-Veru Secures FDA Agreement To Initiate Phase 2 Study Of VERU-111 To Combat COVID-19
* VERU SECURES FDA AGREEMENT TO INITIATE PHASE 2 STUDY OF VERU-111, NOVEL MICROTUBULE DEPOLYMERIZATION DRUG TO COMBAT COVID-19
by Reuters at 5/12/20, 5:54 PMView More →

S&P 500

NASDAQ 100

FTSE 100

QQQ

TESLA

BTC/USD

GBP/USD

GOLD